NCT01652911终止1 期
A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 2
- 主要终点
- To assess the safety of the Sernova Cell Pouch™ in adult participants with Type-1 diabetes receiving islet transplantation for the first time.
研究概览
简要总结
This is an open-label, single arm, non-randomized safety and efficacy study, where participants with Type-1 diabetes will receive the Sernova Cell Pouch™ implanted in the subcutaneous site, two to approximately twelve weeks prior to transplantation of islets into the Cell Pouch™.
The primary objective of this study is to assess the safety of the Sernova Cell Pouch™ in adult participants with Type-1 diabetes receiving islet transplantation for the first time.
Secondary objectives are the following:
- To determine the proportion of subjects implanted with the Cell Pouch™ and transplanted with islets into the Cell Pouch™ who achieve and maintain insulin independence after islet transplantation.
- To obtain preliminary data on the efficacy of the Cell Pouch™ to maintain adequate immunological protection against both allo- and autoimmunity of islet transplant recipients.
- To determine through retrospective analysis comparative metabolic function and engraftment efficiency using patients undergoing standard intraportal islet transplantation under the current alemtuzumab standard of care protocol.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 68 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be eligible the participant must have had T1DM for more than 5 years, complicated by at least 1 of the following situations that persist despite intensive insulin management efforts:
- •Reduced awareness of hypoglycemia, as defined by the absence of adequate autonomic symptoms at plasma glucose levels < 3.0 mmol/L, indicated by, 2 or more episodes of severe hypoglycemia requiring third party assistance within 12 months, a Clarke score ≥4, HYPO score ≥1,000, lability index (LI) ≥400 or combined Hypo/LI >400/300
- •Metabolic instability, characterized by erratic blood glucose levels that interfere with daily activities and or 2 or more hospital visits for diabetic ketoacidosis over the last 12 months.
- •Participants must be capable of understanding the purpose and risks of the study and must sign a statement of informed consent.
排除标准
- •Severe co-existing cardiac disease, characterized by any one of these conditions: (a) recent myocardial infarction (within past 6 months); (b) left ventricular ejection fraction <30%; or (c) evidence of ischemia on functional cardiac exam.
- •Active alcohol or substance abuse, to include cigarette smoking (must be abstinent for 6 months prior to transplant).
- •Psychiatric disorder making the subject not a suitable candidate for transplantation, (e.g., schizophrenia, bipolar disorder, or major depression that is unstable or uncontrolled on current medication).
- •History of non-adherence to prescribed regimens.
- •Active infection including Hepatitis C, Hepatitis B, HIV, TB (subjects with a positive PPD performed within one year of enrollment, and no history of adequate chemoprophylaxis).
- •Any history of or current malignancies except squamous or basal skin cancer.
- •BMI > 35 kg/m2 at screening visit.
- •Age less than 18 or greater than 68 years.
- •Measured glomerular filtration rate (GFR) <60 mL/min/1.73 m
- •Presence or history of macroalbuminuria (>300 mg/g creatinine).
- •Clinical suspicion of nephritic (hematuria, active urinary sediment) or rapidly progressing renal impairment (e.g. Increase in serum creatinine of 25% within the last 3-6 months).
- •Baseline Hb < 105g/L in women, or < 120 g/L in men.
- •Baseline screening liver function tests outside of normal range, with the exception of uncomplicated Gilbert's Syndrome. An initial LFT panel with any values >1.5 times the upper limit of normal (ULN) will exclude a patient without a re-test; a re test for any values between ULN and 1.5 times ULN should be made, and if the values remain elevated above normal limits, the patient will be excluded.
- •Untreated proliferative retinopathy.
- •Positive pregnancy test, intent for future pregnancy or male subjects' intent to procreate, failure to follow effective contraceptive measures, or presently breast feeding.
- •Previous transplant or evidence of significant sensitization on PRA (at the discretion of the investigator).
- •Insulin requirement >1.0 U/kg/day
- •HbA1C >12%.
- •Uncontrolled hyperlipidemia [fasting LDL cholesterol > 3.4 mmol/L, treated or untreated; and/or fasting triglycerides > 2.3 mmol/L].
- •Under treatment for a medical condition requiring chronic use of steroids.
- •Use of coumadin or other anticoagulant therapy (except aspirin) or subject with PT INR > 1.
- •Untreated Celiac disease.
- •Patients with Graves disease will be excluded unless previously adequately treated with radioiodine ablative therapy.
- •Any medical condition that, in the opinion of the clinical investigator, will interfere with the safe participation in the trial.
结局指标
主要结局
To assess the safety of the Sernova Cell Pouch™ in adult participants with Type-1 diabetes receiving islet transplantation for the first time.
时间窗: 3 years post-initial Cell Pouch™ implant.
A tracking log will document adverse events with grading classification as per protocol. For the primary objective endpoint, safety will be assessed following initial Cell Pouch implantation, at the time of islet transplantation, and approximately one month following the initial islet transplantation. Safety will further be assessed at approximately three, six, nine and twelve months and then yearly thereafter.
次要结局
- To obtain preliminary data on the efficacy of the Cell Pouch™.(3 years post-initial CellPouch™)
- To determine the proportion of subjects implanted with the Cell Pouch™ and transplanted with islets into the Cell Pouch™ who achieve insulin independence after islet transplantation.(3 years post-initial Cell Pouch™ implant.)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma SubjectsRelapsed B-cell Acute Lymphoblastic Leukemia, ChildhoodRefractory B-cell Acute Lymphoblastic Leukemia, ChildhoodRelapsed/Refractory B-cell Lymphoma, ChildhoodNCT03265106Shenzhen BinDeBio Ltd.20
Unknown
1 期
A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma SubjectsRelapsed B-cell Acute Lymphoblastic LeukemiaRefractory B-cell Acute Lymphoblastic LeukemiaRelapsed／Refractory B-cell LymphomaNCT03156101Shenzhen BinDeBio Ltd.24
暂停
1 期
GPC3-CAR-T Cells for the Hepatocellular CarcinomaHepatocellular CarcinomaNCT04506983Beijing Tsinghua Chang Gung Hospital12
已完成
2 期
The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaHCCNCT04542837Peking University Cancer Hospital & Institute55
终止
1 期
CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)Refractory and Relapsed B Cell Acute LeukemiaNCT04508842Hebei Yanda Ludaopei Hospital2